# DP-DCT 1.0：A Comparative Clinical Study on the Effect of Dapagliflozin Combined With CGM Versus SMBG on Glycemic Control in Patients With Type 2 Diabetes Mellitus Based on the DP-DCT Platform

Study · id `cardio:ct-nct07595289` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07595289](<https://clinicaltrials.gov/study/NCT07595289>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07595289

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 120 participants.

## Technical summary

Registry record NCT07595289. Randomized; no masking; primary purpose other. Start 2026-08-01 (anticipated); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose other
- Phase: Not applicable
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT07595289, source copy `cardio:ctgov-nct07595289-2026-05-19`, retrieved 2026-10-26)
- Planned start: 2026-08-01 (anticipated) (ClinicalTrials.gov record NCT07595289, source copy `cardio:ctgov-nct07595289-2026-05-19`, retrieved 2026-10-26)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT07595289, source copy `cardio:ctgov-nct07595289-2026-05-19`, retrieved 2026-10-26)
- Completion: 2027-08-01 (anticipated) (ClinicalTrials.gov record NCT07595289, source copy `cardio:ctgov-nct07595289-2026-05-19`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07595289-2026-05-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: DP-DCT 1.0：A Comparative Clinical Study on the Effect of Dapagliflozin Combined With CGM Versus SMBG on Glycemic Control in Patients With Type 2 Diabetes Mellitus Based on the DP-DCT Platform
- Acronym: DP DCT
- Condition: Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug): Dapagliflozin (10mg Tab)
- Intervention (Device): Continuous Glucose Monitoring (CGM)
- Intervention (Other): Self-Monitoring of Blood Glucose (SMBG)
- Lead sponsor: The Third Xiangya Hospital of Central South University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: The Third Xiangya Hospital of Central South University (`cardio:org-the-third-xiangya-hospital-of-central-south-university`)

## Provenance

Content hash: efa4135e0163cef76b1943f8af9b7e3df66dd56ecd5d6d39d818c26779ea39d0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
